NOVEL PYRROLOPYRIMIDINE COMPOUND OR SALT THEREOF, PHARMACEUTICAL COMPOSITION CONTAINING SAME, ESPECIALLY AGENT FOR PREVENTION AND/OR TREATMENT OF TUMORS ETC BASED ON NAE INHIBITORY EFFECT
申请人:TAIHO PHARMACEUTICAL CO., LTD.
公开号:US20170066772A1
公开(公告)日:2017-03-09
An object to be solved by the present invention is to provide a novel pyrrolopyrimidine compound or a salt thereof having an NAE inhibitory action and a cell growth inhibitory effect. The present invention provides a compound or a salt thereof represented by Formula (A), as well as an NAE inhibitor, a pharmaceutical composition, and an antitumor agent comprising the compound or a salt thereof as an active ingredient.
A pyrazolopyrimidine derivative of the formula [I]
wherein R1 is an optionally substituted aromatic ring group, an optionally substituted lower alkyl group or an optionally substituted amino group; R2 is an optionally substituted aromatic ring group; R3 is an optionally substituted lower alkyl group; and R4 is a hydrogen atom, a lower alkyl group, a halogen atom, a nitro group or an amino group;
or a pharmaceutically acceptable salt thereof is useful as an antagonist of CRF receptor.
A pyrazolopyrimidine derivative of the formula [I]
wherein R
1
is an optionally substituted aromatic ring group, an optionally substituted lower alkyl group or an optionally substituted amino group; R
2
is an optionally substituted aromatic ring group; R
3
is an optionally substituted lower alkyl group; and R
4
is a hydrogen atom, a lower alkyl group, a halogen atom, a nitro group or an amino group;
or a pharmaceutically acceptable salt thereof is useful as an antagonist of CRF receptor.
CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES
申请人:Hunt Julianne A.
公开号:US20100184719A1
公开(公告)日:2010-07-22
Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are potent CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In formula I, A-B is an arylamide moiety.
Pyrrolopyrimidine compound or salt thereof and compositions containing the pyrrolopyrimidine compound or salt thereof
申请人:TAIHO PHARMACEUTICAL CO., LTD.
公开号:US10174040B2
公开(公告)日:2019-01-08
A pyrrolopyrimidine compound or a salt thereof and compositions, NAE inhibitors and anti-tumor agents containing the pyrrolopyrimidine compound or a salt thereof. The pyrrolopyrimidine compound or a salt thereof has an NAE inhibitory action and a cell growth inhibitory effect and is represented by Formula (A):